目的 体外筛选设计并合成的抑制效率最佳的短发夹核糖核酸(shRNA)序列,并观察慢病毒介导的环氧合酶-2(COX-2) shRNA对类风湿性关节炎(RA)患者滑膜细胞的影响.方法 首先根据人COX-2 mRNA序列自行设计4对不同的COX-2shRNA序列,然后包装合成分别含有各对序列的慢病毒载体,并将各组慢病毒载体分别转染RA患者滑膜细胞,通过实时定量聚合酶链反应(Real-time PCR)、酶联免疫吸附试验法(ELISA)分别检测转染后细胞基因水平及蛋白质水平的变化,从而筛选最佳抑制序列.结果 以慢病毒为载体介导的COX-2 shRNA基因转染滑膜细胞后,未观察到对细胞生长速度及细胞形态有明显负面影响,转染后COX-2 mRNA表达水平显著下降,从0.83±0.09、0.84±0.06降到0.15 ±0.01、0.15 ±0.01 (P<0.05),相应组别的前列腺素E2(PGE2)[从(160.96±0.23) ng/L降到(84.44±1.02) ng/L]、血管内皮生长因子(VEGF)[从(93.10±0.84) ng/L降到(57.35±1.04) ng/L]、白细胞介素(IL)-1β[从(19.69 ±0.57) ng/L降到(10.60±0.53) ng/L]、肿瘤坏死因子-α(TNF-α)[从(31.52 ±0.33) ng/L降到(14.55 ±0.59) ng/L]表达量显著降低(P<0.05).结论 慢病毒介导的RNA干扰可以显著抑制RA患者滑膜细胞COX-2的表达,从而降低炎性因子的表达量.
Objective Screen the most effective hort hairpin ribonucleic acids (shRNA)sequence,and observe the effects on synovial cells of rheumatoid arthritis (RA) patients after cyclooxygenase-2 (COX-2) shRNA transfection by lentivirus.Methods Design four pairs of different COX-2 shRNA according to the human COX-2 mRNA (NM_000963.2) sequence,package and transfect four kinds of lentivirus with the COX-2 shRNA into synovial cells of RA patient,screen the best shRNA sequence by examine the level of mRNA and protein expression respectively with real-time quantitative polymerase chain reaction (Real-time PCR) and enzyme-linked immuno sorbent assay (ELISA).Results There is no obvious negative influence on cell growth and cell morphology after COX-2 shRNA gene transfection mediated by lentivirus,COX-2 mRNA expression decreases from 0.83 ± 0.09,0.84 ± 0.06 to 0.15 ± 0.01,0.15 ± 0.01 (P 〈 0.05) and protein expression of phenyl glycidyl ether (PGE) 2 [(160.96 ± 0.23) ng/L to (84.44 ± 1.02) ng/L],vascular endothelial growth factor (VEGF) [(93.10 ±0.84) ng/L to (57.35 ± 1.04) ng/L],interleukine (IL)-1β [(19.69 ± 0.57) ng/L to (10.60 ± 0.53) ng/L],tumor necrosis factor α(TNF-α) [(31.52 ± 0.33) ng/L to (14.55 ±0.59) ng/L] decreased significantly (P 〈 0.05).Conclusion Lentivirus mediated ribonucleic acid interference (RNAi)can significantly inhibit COX-2 mRNA expression in synovial cells of RA patients,so as to reduce the expression of inflammatory cytokines.